SSO 2023 Press Coverage: Neoadjuvant pembrolizumab in stage II–III desmoplastic melanoma (SWOG S1512)
At SSO 2023, data was presented indicating that the use of neoadjuvant pembrolizumab could be beneficial in the treatment of desmoplastic melanoma. This approach may increase the chances of successful resection and lower the necessity for additional surgery or radiation therapy. Read more about the research in this ASCO Post article featuring study co-investigator, Vernon K. Sondak, MD, Chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Neoadjuvant Pembrolizumab in Desmoplastic Melanoma
Neoadjuvant pembrolizumab may significantly improve the management of desmoplastic melanoma, increasing the likelihood of successful resection and reducing the need for further surgery or radiation therapy, according to the response data presented at the 2022 ASCO Annual Meeting, with the surgical considerations presented at the 2023 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care.